Rifampin, Rifapentine, and Rifabutin Are Active against Intracellular Periprosthetic Joint Infection-Associated Staphylococcus epidermidis

  • Antimicrob Agents Chemother. 2021 Jan 20;65(2):e01275-20. doi: 10.1128/AAC.01275-20.
Cody Fisher  1  2 ,  Robin Patel  3  4
Affiliations
  • 1. Mayo Clinic Graduate School of Biomedical Sciences, Department of Immunology, Mayo Clinic, Rochester, Minnesota, USA.
  • 2. Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
  • 3. Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA [email protected].
  • 4. Division of Infectious Diseases, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
PMID: 33199387 DOI: 10.1128/AAC.01275-20
Abstract

Staphylococcus epidermidis is a major cause of periprosthetic joint Infection (PJI); its intracellular persistence within osteoblasts may compromise therapy if that therapy is not intracellularly active. The intracellular activity of rifampin, rifapentine, and rifabutin was assessed against five rifampin-susceptible and two rifampin-resistant S. epidermidis isolates. Compared to no treatment, treatment resulted in a ≥2-fold log10 reduction of intracellular rifampin-susceptible, but not rifampin-resistant, S. epidermidis These findings show activity of rifampin, rifapentine, and rifabutin against intraosteoblast PJI-associated S. epidermidis.

Keywords
Staphylococcus epidermidis; intracellular; periprosthetic joint infection; rifamycin.
Products